跳转至内容
Merck

F1308

Sigma-Aldrich

福辛普利 钠

≥98% (HPLC), powder

别名:

(2S,4S)-4-Cyclohexyl-1-(2-{[2-methyl-1-(propanoyloxy)propoxy](4-phenylbutyl)phosphoryl}acetyl)pyrrolidine-2-carboxylic acid, Acecor, Eosinopril, Fosinopril, Monopril, SQ 28555, Secorvas, Staril

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C30H45NO7P · Na
CAS号:
分子量:
585.64
MDL编号:
UNSPSC代码:
12352200
PubChem化学物质编号:
NACRES:
NA.77

方案

≥98% (HPLC)

表单

powder

储存条件

desiccated

颜色

white to off-white

溶解性

H2O: >20 mg/mL

创始人

Bristol-Myers Squibb

储存温度

−20°C

SMILES字符串

O=C([O-])[C@H]1N(C(CP(CCCCC2=CC=CC=C2)(O[C@@H](C(C)C)OC(CC)=O)=O)=O)C[C@H](C3CCCCC3)C1.[Na+]

InChI

1S/C30H46NO7P.Na/c1-4-28(33)37-30(22(2)3)38-39(36,18-12-11-15-23-13-7-5-8-14-23)21-27(32)31-20-25(19-26(31)29(34)35)24-16-9-6-10-17-24;/h5,7-8,13-14,22,24-26,30H,4,6,9-12,15-21H2,1-3H3,(H,34,35);/q;+1/p-1/t25-,26+,30+,39?;/m1./s1

InChI key

TVTJZMHAIQQZTL-TXDYNIFHSA-M

正在寻找类似产品? 访问 产品对比指南

一般描述

Fosinopril lowers blood pressure and functions as an antihypertensive agent. It is an ester prodrug. Fosinopril is metabolised by the liver and excreted from the body by liver and kidney. It is used to treat heart failure.

生化/生理作用

Fosinopril is an angiotensin converting enzyme (ACE) inhibitor.
Fosinopril is an angiotensin converting enzyme (ACE) inhibitor. Fosinopril is also known to inhibit the activity of the peptide transporter PEPT2.

特点和优势

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

象形图

Health hazardExclamation mark

警示用语:

Warning

危险声明

危险分类

Eye Irrit. 2 - Repr. 2

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

Not applicable

闪点(°C)

Not applicable


历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Disposition of fosinopril sodium in healthy subjects
Singhv SM, et al.
British Journal of Clinical Pharmacology, 25(1), 9-15 (1988)
S Giovannini et al.
The journal of nutrition, health & aging, 14(6), 457-460 (2010-07-10)
The present study evaluates the effects of a 6-month treatment with an ACE-inhibitor (ie, fosinopril) on serum concentrations of total IGF-1 and IGF binding protein (IGFBP)-3 in older adults at high risk for cardiovascular disease. Data are from the Trial
Patrick Rossignol et al.
Hypertension (Dallas, Tex. : 1979), 60(2), 339-346 (2012-07-11)
Optimal blood pressure (BP) targets are still controversial in end-stage renal disease. Recent data have highlighted shortcomings of the usual BP hypothesis in other patient populations and emphasized the importance of visit-to-visit variability of BP in predicting cardiovascular events. The
Ya-chen Zhang et al.
Cell biochemistry and biophysics, 64(3), 205-211 (2012-06-26)
Fosinopril, an angiotensin-converting enzyme inhibitor, is known to attenuate cardiomyopathy induced by doxorubicin (DOX); however, the mechanisms of this cardioprotection are not fully elucidated yet. In the present study, experimental cardiomyopathy was induced in rats by administration of DOX with
Dinesh Shrikrishna et al.
Chest, 146(4), 932-940 (2014-02-22)
Skeletal muscle impairment is a recognized complication of COPD, predicting mortality in severe disease. Increasing evidence implicates the renin-angiotensin system in control of muscle phenotype. We hypothesized that angiotensin-converting enzyme (ACE) inhibition would improve quadriceps function and exercise performance in

商品

We offer many products related to angiotensin receptors for your research needs.

We offer many products related to angiotensin receptors for your research needs.

We offer many products related to angiotensin receptors for your research needs.

We offer many products related to angiotensin receptors for your research needs.

查看所有结果

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门